View Future GrowthDuality Biotherapeutics 過去の業績過去 基準チェック /06Duality Biotherapeuticsの収益は年間平均-303.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間36.2% 16.5%割合で 増加しています。主要情報-303.21%収益成長率-29.80%EPS成長率Biotechs 業界の成長17.04%収益成長率16.47%株主資本利益率-97.19%ネット・マージン-130.43%前回の決算情報30 Jun 2025最近の業績更新お知らせ • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026すべての更新を表示Recent updatesお知らせ • Jun 05Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026, at 09:30 China Standard Time. Location: board room, 11/f, building a, no. 868 yinghua road, pudong new area, shanghai Chinaお知らせ • May 29Duality Biotherapeutics, Inc. (SEHK:9606) commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.Duality Biotherapeutics, Inc. (SEHK:9606) commences share repurchases on May 26, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 20, 2025. As per the mandate, the company is authorized to repurchase up to 8,803,626 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value and/or earnings per share for the company. The repurchases will be financed out of the funds legally available for such purpose in accordance with its Memorandum and Articles of Association and the laws of the Cayman Islands. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 20, 2025, the company had 88,036,264 shares in issue. On May 19, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to $40 million worth of its shares. The program will be funded from company's internal funds. The repurchased shares will be held as treasury shares.お知らせ • Apr 10DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast CancerDualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for trastuzumab pamirtecan as second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer. The application is based on positive interim results from the pivotal Phase III clinical trial (Study DB-1303-O-3001). The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Trastuzumab pamirtecan ("T-Pam", also known as BNT323 or DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which is being developed by BioNTech and DualityBio. Trastuzumab pamirtecan was built from DualityBio's proprietary Duality Immune Toxin Antibody Conjugates ("DITAC") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells, making it a potential target for innovative cancer therapeutics. The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window. Trastuzumab pamirtecan is currently being evaluated in multiple solid tumor types and innovative treatment combinations, including two global pivotal clinical trials in first-line HER2-low, hormone receptor positive ("HR+") metastatic breast cancer (DYNASTY-Breast02; NCT06018337) and second-line endometrial cancer (BNT323-01; NCT06340568), a novel-novel combination Phase 1/2 clinical trial (BNT323-03; NCT06827236) evaluating trastuzumab pamirtecan in combination with pumitamig in HR-positive or –negative, HER2-low, -ultra-low, or -null advanced/metastatic breast cancer and a Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (NCT06340568).お知らせ • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026収支内訳Duality Biotherapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:DUTB.F 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費30 Jun 252,170-2,83121180931 Mar 252,056-1,94118581231 Dec 241,941-1,05015981531 Dec 231,787-35863559質の高い収益: DUTB.Fは現在利益が出ていません。利益率の向上: DUTB.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DUTB.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: DUTB.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: DUTB.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: DUTB.Fは現在利益が出ていないため、自己資本利益率 ( -97.19% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/01/17 17:25終値2025/10/20 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Duality Biotherapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Qianlan ZhuCGS InternationalLily WangCGS InternationalLily WangChina Galaxy International Securities (Hong Kong)7 その他のアナリストを表示
お知らせ • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026
お知らせ • Jun 05Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026Duality Biotherapeutics, Inc., Annual General Meeting, Jun 26, 2026, at 09:30 China Standard Time. Location: board room, 11/f, building a, no. 868 yinghua road, pudong new area, shanghai China
お知らせ • May 29Duality Biotherapeutics, Inc. (SEHK:9606) commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.Duality Biotherapeutics, Inc. (SEHK:9606) commences share repurchases on May 26, 2026, under the program mandated by the shareholders in the Annual General Meeting held on June 20, 2025. As per the mandate, the company is authorized to repurchase up to 8,803,626 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value and/or earnings per share for the company. The repurchases will be financed out of the funds legally available for such purpose in accordance with its Memorandum and Articles of Association and the laws of the Cayman Islands. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual general Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 20, 2025, the company had 88,036,264 shares in issue. On May 19, 2026, the company announced a share repurchase program. Under the program, the company will repurchase up to $40 million worth of its shares. The program will be funded from company's internal funds. The repurchased shares will be held as treasury shares.
お知らせ • Apr 10DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast CancerDualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for trastuzumab pamirtecan as second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer. The application is based on positive interim results from the pivotal Phase III clinical trial (Study DB-1303-O-3001). The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis. Trastuzumab pamirtecan ("T-Pam", also known as BNT323 or DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which is being developed by BioNTech and DualityBio. Trastuzumab pamirtecan was built from DualityBio's proprietary Duality Immune Toxin Antibody Conjugates ("DITAC") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells, making it a potential target for innovative cancer therapeutics. The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window. Trastuzumab pamirtecan is currently being evaluated in multiple solid tumor types and innovative treatment combinations, including two global pivotal clinical trials in first-line HER2-low, hormone receptor positive ("HR+") metastatic breast cancer (DYNASTY-Breast02; NCT06018337) and second-line endometrial cancer (BNT323-01; NCT06340568), a novel-novel combination Phase 1/2 clinical trial (BNT323-03; NCT06827236) evaluating trastuzumab pamirtecan in combination with pumitamig in HR-positive or –negative, HER2-low, -ultra-low, or -null advanced/metastatic breast cancer and a Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (NCT06340568).
お知らせ • Mar 11Duality Biotherapeutics, Inc. to Report Fiscal Year 2025 Results on Mar 23, 2026Duality Biotherapeutics, Inc. announced that they will report fiscal year 2025 results on Mar 23, 2026